Replies to post #645511 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

The fudster still doesn't understand the concept of crossover and rGBM efficacy, and would continue to fud on things he doesn't understand. He also seems to fud over the irrelevant topic of importance of PFS over OS. The data is king and the fud is useless.

[flipper44]

Preschool argument

“if it was LP would be shouting it out.” Exwannabe

Obviously you need unconfounded numbers from the ECA comparison, which allow QALY valuation, but your certainty that the original OS comparison failed may very well also be wrong (even with crossover impact) it’s looking that way.

[supersteve13]

Hey ex, can you pause your criticism of his post long enough to let us know if you’ve learned to identify trial endpoints yet, such as in the EF-11 optune study? :)